A 46-year-old white male with small cell lung cancer (SCLC) limited to the thorax developed autoimmune thrombocytopenic purpura (AITP), following a cyclophosphamide, paclitaxel and G-CSF-containing regimen for peripheral blood stem cell (PBSC) mobilization. AITP associated with small or non-small cell lung cancer has been reported. We considered that the AITP in this case may be a part of paraneoplastic syndrome, which is frequently seen in patients with SCLC. The patient received HDC and autologous PBSC transplantation (APBSCT) for SCLC and the AITP resolved following transplantation, thus supporting the concept of HDC + APBSCT for the treatment of autoimmune diseases.
ITP is a well-known entity involving immune-mediated destruction of platelets. The majority of autoantibodies are of the IgG class and directed against the GPIIb/IIIa structural complex of the platelets. 1 Although in the majority of the cases a cause for the immune destruction and excess auto-antibody formation cannot be demonstrated, in some disorders such as rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Graves disease, pernicious anemia, myasthenia gravis auto-antibodies have been documented. Immune thrombocytopenia is frequently encountered in lymphoproliferative disorders especially in nonHodgkin's lymphomas and chronic lymphocytic leukemia. 1 In patients with lymphoproliferative and non-lymphoproliferative disorders, non-immune thrombocytopenia may appear in the context of concomitant chemotherapy or tumor infiltration of bone marrow preceding bone marrow Correspondence: Dr T Demirer, Ankara University Medical School, Dept of Hematology/Oncology and Bone Marrow Transplant Unit, Ibn-i Sina Hospital, Sıhhıye 06100, Ankara, Turkey Received 11 January 1998; accepted 23 March 1999 failure.
1 AITP may also develop following autologous, allogeneic or syngeneic marrow or stem cell transplantation as an immunohematologic complication and may occur as early as the day of transplantation or as late as several years afterwards. 2 Here we describe a case of AITP in a patient with SCLC, which developed after a cyclophosphamide and paclitaxelcontaining chemotherapy regimen for PBSC mobilization and resolved following an APBSCT.
Case report
A 46-year-old white male was diagnosed with SCLC in March 1998. Staging work-up, including thoraco-abdominal computerized tomography (CT) and cranial CT was consistent with SCLC limited to thorax. CBC and serum biochemistry values were in the normal ranges before induction chemotherapy (WBC of 8 × 10 
Discussion
Thrombocytopenia is caused by one of three mechanismsdecreased bone marrow production, increased splenic sequestration, or accelerated destruction of platelets. 1, 3 Disorders that injure stem cells or prevent their proliferation in marrow frequently cause thrombocytopenia. They usually affect multiple hematopoietic cell lines so that thrombocytopenia is accompanied by varying degrees of anemia and leukopenia. The most common causes of decreased platelet production are marrow aplasia, fibrosis, or infiltration with malignant cells, all of which produce highly characteristic marrow abnormalities. 1, 3, 4 Splenic sequestration is one of the important causes of thrombocytopenia. Since one-third of the platelet mass is normally sequestrated in the spleen, splenectomy will increase the platelet count by 30%. In contrast, when the spleen enlarges, the fraction of sequestrated platelets increases, lowering the platelet count. Many patients with leukemia, lymphoma or a myeloproliferative syndrome have both marrow infiltration and splenomegaly and develop thrombocytopenia from a combination of impaired marrow production and splenic sequestration of platelets.
1 Accelerated platelet destruction may be due to either non-immunologic or immunologic factors. Abnormal vessels, fibrin thrombi, or intravascular prostheses can all shorten platelet survival and cause non-immunologic thrombocytopenia as is seen in patients with vasculitis, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. In addition, platelets coated with antibody, immune complexes, or complement are rapidly cleared by mononuclear phagocytes in the spleen or other tissues, inducing immunologic thrombocytopenia. The most common causes of immunologic thrombocytopenia are viral or bacterial infections, drugs, and a chronic autoimmune disorder referred to as ITP. Patients with immunologic thrombocytopenia do not usually have splenomegaly and have an active bone marrow with an increased number of megakaryocytes. 1, 3, 4 Patients with SCLC have a wide spectrum of paraneoplastic syndromes such as secondary endocrinopathies, Guillian-Barré syndrome, neuropathies, retinopathies due to production of peptide hormones. 5 In this case, we could not exclude a paraneoplastic phenomenon. A literature search showed that lung cancer, either small cell or nonsmall cell, may be associated with AITP.
6-8 Therefore, we considered that the AITP in our patient may have been due to SCLC in which paraneoplastic syndromes are frequently seen. Autoimmune antibody formation due to paraneoplastic syndrome in a patient with SCLC is conceivable, and paraneoplastic syndrome in our patient may have triggered the formation of anti-platelet antibodies and as a result, AITP.
Intermediate high-dose CY has been used successfully for the treatment of refractory ITP. 9 CY + paclitaxel followed by rhG-CSF has been used previously for PBSC mobilization in many patients with breast and ovarian cancer and AITP or isolated thrombocytopenia was not reported in any of these cases. 10 It is interesting that in our case AITP developed following CY (4 g/m 2 × 1) and a paclitaxel-containing regimen for PBSC mobilization and was not present before. Therefore, post-chemotherapy immunologic dysregulation may be a trigger for the development of AITP. Recently, Marmont et al 11 reported a case of refractory thrombocytopenic purpura of 10 years duration which did not respond to autologous, T cell-depleted marrow transplantation following conditioning with thiotepa and CY. Lim et al 12 reported two patients with refractory ITP treated with routine conditioning with CY 200 mg/kg over 4 days, and subsequently reinfused with their own mobilized PBSCs. Complete, steroid-independent platelet remission was obtained, but unfortunately both patients have subsequently relapsed after 12 and 18 months, respectively. One of the most interesting case reports of AITP is that of a patient whose donor had compensated AITP prior to the transplant, following which the recipient developed decompensated AITP post transplant. 13 This study suggested that the immune defect in autoimmune thrombocytopenia can be transferred in cells capable of proliferating in a bone marrow graft. 13 AITP in the current case resolved following HDC + APBSCT and the patient had stable platelet counts of over 150 × 10 9 /l. APBSCT has been used for treatment of auto-immune diseases such as lupus, scleroderma and systemic sclerosis, and improvement in the clinical course following APBSCT in these patients has been reported by several authors.
14 Based on the literature, results of HDC + APBSCT for treatment of refractory ITP are not encouraging. Our case was not refractory ITP and it was associated with SCLC which may represent the clinical picture of paraneoplastic syndrome. Therefore, we do not suggest HDC + APBSCT for the treatment of the AITP but disappearance of the AITP after APBSCT is interesting and supports the concept of HDC + APBSCT with or without stem cell manipulation for the treatment of auto-immune diseases.
